ProSomnus Sleep Technologies is dedicated to helping dentists treat the growing number of patients with Obstructive Sleep Apnea
San Francisco, CA, October 3, 2016 – ProSomnus Sleep Technologies, featuring the award-winning MicrO2® Obstructive Sleep Apnea and Snore Device, today announced that it has separated from MicroDental Laboratories. This strategic move enables ProSomnus to operate as a standalone business and concentrate resources on partnering with dentists to treat the rapidly growing number of patients with Obstructive Sleep Apnea.
Obstructive Sleep Apnea (OSA) is a Sleep Breathing Disorder affecting an estimated 20 million adults in the United States. OSA has been linked with an increased risk of stroke, cardiovascular problems, motor vehicle accidents, depression, memory loss, and snoring. The economic impact of OSA is estimated to be between $65 and $165 Billion per year.
“ProSomnus invents and manufactures devices that enable dentists to treat more patients who are suffering from OSA. Tens of millions of adults have undiagnosed OSA, millions of adults have abandoned CPAP, and dentists can help,” commented Len Liptak, CEO of ProSomnus Sleep Technologies. “Separating from MicroDental Laboratories enables ProSomnus to accelerate development of the key products, processes, and programs that are integral to this plan.”
ProSomnus Sleep Technologies is a member of HealthpointCapital’s portfolio of investments. HealthpointCapital is a value-driven, research-oriented private equity firm that has an exceptional track record of investing in innovative dental and orthopedic medical device companies.
“A few years ago, HealthpointCapital identified the Obstructive Sleep Apnea Market as an attractive opportunity,” noted Laing Rikkers, Managing Director at HealthpointCapital. “HealthpointCapital invests in innovative device companies that are addressing underserved healthcare issues, and ProSomnus fits this profile. We look forward to partnering with the leadership team at ProSomnus to expand the oral appliance therapy segment of the Sleep Apnea Market.”
About ProSomnus Sleep Technologies
ProSomnus Sleep Technologies designs, manufactures and markets innovative intraoral sleep devices that dentists use to treat patients diagnosed with Obstructive Sleep Apnea. The company’s flagship product is the MicrO2® Sleep Device. The MicrO2 Sleep Device is a FDA Cleared Class II Medical Device that is smaller, stronger, more biocompatible, and more precise than predicate intraoral Sleep Apnea devices, allowing dentists to get patients into therapy faster, and with greater comfort and simplicity. The MicrO2 has been used to treat thousands of patients, with clinical performance that has been validated in controlled trials, retrospective cohort studies, and numerous clinical case reports.
